First US Lucentis Biosimilar Expected By Year End, Roche Confirms
Samsung Bioepis’ SB11 Biosimilar Pending With FDA
Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.
